Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted therapies for moderate to severe rheumatoid arthritis
2025-520721-21-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of lutikizumab and ravagalimab in rheumatoid arthritis (RA) (4 arms), sponsored by AbbVie Inc. Primary endpoint: ACR50 response at Week 12. Planned start Oct 2025; status: authorised.
02
Drugs
lutikizumabravagalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-520721-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520721-21-00.